FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2079544072> ?p ?o ?g. }

• W2079544072 endingPage "2777" @default.
• W2079544072 startingPage "2769" @default.
• W2079544072 abstract "Ocular surface disease (OSD) is a common side effect of ophthalmic medications containing the preservative benzalkonium chloride (BAK). Little is known whether and how glaucoma treatment patterns and annual costs vary based on the presence of BAK. The objective of this analysis was to estimate first-year treatment costs among new initiators of topical prostaglandin analogs in a managed care population.A model was developed to estimate first-year direct medical costs associated with glaucoma prescriptions and outpatient ophthalmic care. Patients were identified from a pharmacy claims database, covering more than 75 million individuals, if they initiated therapy with one of three prostaglandin analog products between November 1, 2007 and April 30, 2008. Patients needed to have at least 6 months of prior claims data in which there were no glaucoma therapy claims and at least 12 months of follow-up data available after the initial claim. Patients were excluded if they were not continuously eligible for pharmacy benefits throughout this 18-month period. Published studies were used to estimate outpatient visit-related health care resource use, and costs for prescription medications and health care resource use were derived from standard, published benchmarks.The database analysis identified 9398 patients meeting study criteria, 45% (n = 4230) of whom remained on their initial prostaglandin therapy for 12 months after initiation. Adjunctive intraocular pressure lowering therapy was needed in 23.6%, 18.5%, and 13.3% of bimatoprost, latanoprost, and BAK-free travoprost patients, respectively. Median numbers of days to the first prescription filled for adjunctive therapy (if required) were 72.5, 74.0, and 125.0 for patients initiating on bimatoprost, latanoprost, and BAK-free travoprost. Total estimated first-year costs were $1973, $1807, and $1739 for patients initiating therapy with bimatoprost, latanoprost, and BAK-free travoprost. Findings were consistent through sensitivity analysis.A BAK-free prostaglandin analog may permit longer duration of monotherapy and be associated with lower first-year direct treatment costs. Use of a claims database and the selection of new initiators of prostaglandin analogs limit projecting findings to all glaucoma patients." @default.
• W2079544072 created "2016-06-24" @default.
• W2079544072 creator A5040745103 @default.
• W2079544072 creator A5045266317 @default.
• W2079544072 creator A5056831783 @default.
• W2079544072 date "2010-11-02" @default.
• W2079544072 modified "2023-09-24" @default.
• W2079544072 title "First-year treatment costs among new initiators of topical prostaglandin analog identified from November 2007 through April 2008" @default.
• W2079544072 cites W10727480 @default.
• W2079544072 cites W1966829052 @default.
• W2079544072 cites W1968292175 @default.
• W2079544072 cites W1974991464 @default.
• W2079544072 cites W1976180471 @default.
• W2079544072 cites W1984656953 @default.
• W2079544072 cites W1984673463 @default.
• W2079544072 cites W1985992536 @default.
• W2079544072 cites W1989033877 @default.
• W2079544072 cites W1994970293 @default.
• W2079544072 cites W2006971510 @default.
• W2079544072 cites W2026975672 @default.
• W2079544072 cites W2035689780 @default.
• W2079544072 cites W2038661707 @default.
• W2079544072 cites W2042978277 @default.
• W2079544072 cites W2044408581 @default.
• W2079544072 cites W2068598411 @default.
• W2079544072 cites W2070099990 @default.
• W2079544072 cites W2078889609 @default.
• W2079544072 cites W2091063199 @default.
• W2079544072 cites W2101518722 @default.
• W2079544072 cites W2109238714 @default.
• W2079544072 cites W2135469914 @default.
• W2079544072 cites W2153850712 @default.
• W2079544072 cites W2155227897 @default.
• W2079544072 cites W2158502913 @default.
• W2079544072 cites W2166208118 @default.
• W2079544072 cites W2171156248 @default.
• W2079544072 cites W2408121173 @default.
• W2079544072 cites W3025522717 @default.
• W2079544072 doi "https://doi.org/10.1185/03007995.2010.531254" @default.
• W2079544072 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21043550" @default.
• W2079544072 hasPublicationYear "2010" @default.
• W2079544072 type Work @default.
• W2079544072 sameAs 2079544072 @default.
• W2079544072 citedByCount "6" @default.
• W2079544072 countsByYear W20795440722012 @default.
• W2079544072 countsByYear W20795440722014 @default.
• W2079544072 countsByYear W20795440722017 @default.
• W2079544072 crossrefType "journal-article" @default.
• W2079544072 hasAuthorship W2079544072A5040745103 @default.
• W2079544072 hasAuthorship W2079544072A5045266317 @default.
• W2079544072 hasAuthorship W2079544072A5056831783 @default.
• W2079544072 hasConcept C104863432 @default.
• W2079544072 hasConcept C118487528 @default.
• W2079544072 hasConcept C142724271 @default.
• W2079544072 hasConcept C160735492 @default.
• W2079544072 hasConcept C162324750 @default.
• W2079544072 hasConcept C194828623 @default.
• W2079544072 hasConcept C2426938 @default.
• W2079544072 hasConcept C2775919038 @default.
• W2079544072 hasConcept C2776521421 @default.
• W2079544072 hasConcept C2776740260 @default.
• W2079544072 hasConcept C2777336333 @default.
• W2079544072 hasConcept C2778527774 @default.
• W2079544072 hasConcept C2779526769 @default.
• W2079544072 hasConcept C2780276452 @default.
• W2079544072 hasConcept C2781092963 @default.
• W2079544072 hasConcept C2908647359 @default.
• W2079544072 hasConcept C50522688 @default.
• W2079544072 hasConcept C512399662 @default.
• W2079544072 hasConcept C71924100 @default.
• W2079544072 hasConcept C98274493 @default.
• W2079544072 hasConcept C99454951 @default.
• W2079544072 hasConceptScore W2079544072C104863432 @default.
• W2079544072 hasConceptScore W2079544072C118487528 @default.
• W2079544072 hasConceptScore W2079544072C142724271 @default.
• W2079544072 hasConceptScore W2079544072C160735492 @default.
• W2079544072 hasConceptScore W2079544072C162324750 @default.
• W2079544072 hasConceptScore W2079544072C194828623 @default.
• W2079544072 hasConceptScore W2079544072C2426938 @default.
• W2079544072 hasConceptScore W2079544072C2775919038 @default.
• W2079544072 hasConceptScore W2079544072C2776521421 @default.
• W2079544072 hasConceptScore W2079544072C2776740260 @default.
• W2079544072 hasConceptScore W2079544072C2777336333 @default.
• W2079544072 hasConceptScore W2079544072C2778527774 @default.
• W2079544072 hasConceptScore W2079544072C2779526769 @default.
• W2079544072 hasConceptScore W2079544072C2780276452 @default.
• W2079544072 hasConceptScore W2079544072C2781092963 @default.
• W2079544072 hasConceptScore W2079544072C2908647359 @default.
• W2079544072 hasConceptScore W2079544072C50522688 @default.
• W2079544072 hasConceptScore W2079544072C512399662 @default.
• W2079544072 hasConceptScore W2079544072C71924100 @default.
• W2079544072 hasConceptScore W2079544072C98274493 @default.
• W2079544072 hasConceptScore W2079544072C99454951 @default.
• W2079544072 hasIssue "12" @default.
• W2079544072 hasLocation W20795440721 @default.
• W2079544072 hasLocation W20795440722 @default.
• W2079544072 hasOpenAccess W2079544072 @default.
• W2079544072 hasPrimaryLocation W20795440721 @default.

• next